Last reviewed · How we verify
Medicinal cannabis in combination with oxycodon
Medicinal cannabis in combination with oxycodone, marketed by Leiden University Medical Center, holds a unique position in the pain management market. The key composition patent, expiring in 2028, provides a significant barrier to entry for competitors. However, the lack of detailed clinical trial results and revenue data poses a primary risk in assessing the drug's long-term market viability.
At a glance
| Generic name | Medicinal cannabis in combination with oxycodon |
|---|---|
| Sponsor | Leiden University Medical Center |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: